• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Optum Rx Further Simplifies Consumer Access to Prescription Drugs

    3/19/25 7:00:00 AM ET
    $UNH
    Medical Specialities
    Health Care
    Get the next $UNH alert in real time by email

    Optum Rx is committed to making prescription drugs more affordable and the pharmacy experience simpler for consumers with chronic conditions, eliminating up to 25% of reauthorizations, which is equal to more than 10% of overall pharmacy prior authorizations.

    "Optum Rx is taking meaningful steps to simplify patient experiences and increase access to critical medications," said Patrick Conway, M.D., chief executive officer, Optum Rx "These changes mean easier access to medications for consumers, less work for pharmacists and physicians, and a simplified system focused on clinical quality."

    The initiative focuses first on approximately 80 drugs, and Optum Rx will work with physicians and pharmacists to expand the list over time.

    Medication authorizations are important for ensuring safe, appropriate, evidence-supported use of drugs. Some reauthorizations are necessary for drugs that have safety concerns, need ongoing monitoring for dose adjustments, require additional tests or may have alternative therapy considerations.

    For example, new drugs developed for Alzheimer's disease carry risks for the brain, and long-term effectiveness is not clear. For these treatments, ongoing review is important for patients, payers and physicians. In contrast, once a genetic condition like cystic fibrosis is confirmed through testing, there is minimal additional value in reauthorizing an effective, lifelong treatment.

    Fighting to Lower Drug Costs: What We've Done for Consumers

    In addition to the initiative announced today, Optum Rx continues to fight the high and ever-increasing drug prices set by pharmaceutical companies through both negotiation and innovative, cost-cutting tools such as:

    1. Optum financial assistance programs, including Optum Savings IQ which matches eligible Optum Specialty patients with financial resources and programs to lower their out-of-pocket costs for specialty medications. In 2024, the programs helped eligible consumers save $1.3 billion and reduced the average out-of-pocket cost to $5.
    2. Critical Drug Affordability List, which caps out-of-pocket costs for people on over 290 lifesaving medications; our consumers now pay less than $18 per month on average for insulin and typically $5 or less for most drugs.
    3. Price Edge, a digital price comparison tool that has generated $224 million in consumer savings, with an average savings of $50 per consumer.
    4. PreCheck MyScript, which automatically scans drug prices to provide real-time price information and ensure consumers get the best price for their medications, generating consumer savings of $119 per prescription fill and client savings of $266.
    5. Proactive Savings Alerts, which notifies consumers of savings opportunities averaging $42 per prescription.
    6. MyScript Finder, which averages $58 in savings when used, enables consumers to see the price of their prescribed medication, as well as the pharmacies and medication alternatives that could save them money.

    About Optum

    Optum is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. With more than 210,000 people worldwide, Optum delivers intelligent, integrated solutions that help to modernize the health system and improve overall population health. Optum is part of UnitedHealth Group. For more information, visit www.Optum.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250319970580/en/

    Media Contact: [email protected]

    Get the next $UNH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UNH

    DatePrice TargetRatingAnalyst
    5/21/2025$270.00Hold → Reduce
    HSBC Securities
    5/19/2025$308.00Buy → Hold
    TD Cowen
    5/14/2025Strong Buy → Mkt Perform
    Raymond James
    5/14/2025$350.00Buy → Neutral
    BofA Securities
    4/22/2025$490.00Buy → Hold
    HSBC Securities
    4/21/2025Buy → Hold
    Argus
    1/10/2025$595.00Hold → Buy
    HSBC Securities
    1/6/2025$625.00 → $610.00Buy
    Truist
    More analyst ratings

    $UNH
    Financials

    Live finance-specific insights

    See more
    • UnitedHealth Group Announces Leadership Transition

      Stephen J. Hemsley named Chief Executive Officer Company suspends 2025 outlook as medical expenditures expected to be higher than anticipated Company expects to return to growth in 2026 UnitedHealth Group (NYSE:UNH) today announced the appointment of Stephen J. Hemsley as its chief executive officer, effective immediately, following Andrew Witty's decision to step down as CEO for personal reasons. Hemsley, who served as company CEO from 2006-2017, will remain chairman of the company's Board of Directors and Witty will serve as a senior adviser to Hemsley. "We are grateful for Andrew's stewardship of UnitedHealth Group, especially during some of the most challenging times any company

      5/13/25 6:30:00 AM ET
      $UNH
      Medical Specialities
      Health Care
    • UnitedHealth Group Reports First Quarter 2025 Results and Revises Full Year Guidance

      Revised 2025 Earnings Outlook to $24.65 to $25.15 Per Share, Adjusted Earnings $26 to $26.50 Per Share First Quarter Earnings were $6.85 Per Share, Adjusted Earnings $7.20 Per Share Revenues of $109.6 Billion Grew $9.8 Billion Year-Over-Year Consumers Served by UnitedHealthcare Increased by 780,000 Year to Date Optum Health Continues to Expect to Serve 650,000 New Value-Based Care Patients in 2025 UnitedHealth Group (NYSE:UNH) reported first quarter 2025 results and revised its outlook for the year. "UnitedHealth Group grew to serve more people more comprehensively but did not perform up to our expectations, and we are aggressively addressing those challenges to position us well

      4/17/25 5:55:00 AM ET
      $UNH
      Medical Specialities
      Health Care
    • AM Best Affirms Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries

      AM Best has affirmed the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a" (Excellent) and the Long- and Short-Term Issuer Credit Ratings (Long-Term IR; Short-Term IR) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) (NYSE:UNH). Concurrently, AM Best has affirmed the Financial Strength Rating (FSR) of A+ (Superior) and the Long-Term ICRs of "aa-" (Superior) of the health and dental insurance subsidiaries of UnitedHealth Group, collectively referred to as UnitedHealthcare. The outlook of these Credit Ratings (ratings) is stable. (See link below for a detailed listing of the companies and ratings.) The ratings reflect UnitedHealthcare's balance sheet strength, wh

      3/12/25 4:20:00 PM ET
      $UNH
      Medical Specialities
      Health Care

    $UNH
    Leadership Updates

    Live Leadership Updates

    See more
    • UnitedHealth Group Investors: Please contact the Portnoy Law Firm to recover your losses. July 7, 2025 Deadline to file Lead Plaintiff Motion.

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) --  The Portnoy Law Firm advises UnitedHealth Group ("UnitedHealth" or the "Company") (NYSE:UNH) UnitedHealth investors have until July 7, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. UnitedHealth is a health insurance and health care services pr

      5/13/25 5:59:56 PM ET
      $UNH
      Medical Specialities
      Health Care
    • Charlie Baker Joins UnitedHealth Group's Board of Directors

      UnitedHealth Group (NYSE:UNH) announced Charlie Baker, the former governor of Massachusetts and a prominent former health care executive, has been appointed to its Board of Directors, effective immediately. "Charlie Baker's leadership and deep health care experience will serve UnitedHealth Group well in its efforts to make the health system work better for everyone," said UnitedHealth Group Board Chairman Stephen J. Hemsley. "Charlie is an outstanding addition to our board given his proven track record in government and in leading businesses in the health sector, including care delivery and benefits." "UnitedHealth Group has unique capabilities to improve health care outcomes, lower cos

      11/3/23 4:00:00 PM ET
      $UNH
      Medical Specialities
      Health Care
    • DNAnexus Announces Appointment of Thomas Laur as CEO

      Proven healthcare executive brings decades of experience leading successful software, data, and services companies Richard Daly remains actively involved as a member of the Board of Directors DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data management and analysis software, today announced that Thomas Laur has been appointed Chief Executive Officer and member of the company's Board of Directors, effective September 11, 2023. Mr. Laur succeeds Richard Daly, who has overseen the company's significant growth since 2013 and will remain an active advisor and a member of the Board of Directors. "It has been the greatest privilege of my life to have led the evol

      9/12/23 9:02:00 AM ET
      $UNH
      Medical Specialities
      Health Care

    $UNH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UnitedHealth downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded UnitedHealth from Hold to Reduce and set a new price target of $270.00

      5/21/25 8:41:18 AM ET
      $UNH
      Medical Specialities
      Health Care
    • UnitedHealth downgraded by TD Cowen with a new price target

      TD Cowen downgraded UnitedHealth from Buy to Hold and set a new price target of $308.00

      5/19/25 8:51:13 AM ET
      $UNH
      Medical Specialities
      Health Care
    • UnitedHealth downgraded by Raymond James

      Raymond James downgraded UnitedHealth from Strong Buy to Mkt Perform

      5/14/25 8:59:11 AM ET
      $UNH
      Medical Specialities
      Health Care

    $UNH
    SEC Filings

    See more
    • UnitedHealth Group Incorporated filed SEC Form 8-K: Leadership Update

      8-K - UNITEDHEALTH GROUP INC (0000731766) (Filer)

      5/21/25 4:34:59 PM ET
      $UNH
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by UnitedHealth Group Incorporated

      DEFA14A - UNITEDHEALTH GROUP INC (0000731766) (Filer)

      5/20/25 6:01:10 AM ET
      $UNH
      Medical Specialities
      Health Care
    • UnitedHealth Group Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - UNITEDHEALTH GROUP INC (0000731766) (Filer)

      5/14/25 6:01:00 AM ET
      $UNH
      Medical Specialities
      Health Care

    $UNH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $UNH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $UNH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $UNH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by UnitedHealth Group Incorporated (Amendment)

      SC 13G/A - UNITEDHEALTH GROUP INC (0000731766) (Subject)

      2/13/24 5:16:09 PM ET
      $UNH
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by UnitedHealth Group Incorporated (Amendment)

      SC 13G/A - UNITEDHEALTH GROUP INC (0000731766) (Subject)

      2/9/24 10:05:20 AM ET
      $UNH
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by UnitedHealth Group Incorporated (Amendment)

      SC 13G/A - UNITEDHEALTH GROUP INC (0000731766) (Subject)

      2/9/23 12:39:51 PM ET
      $UNH
      Medical Specialities
      Health Care
    • President & CFO Rex John F bought $4,999,919 worth of shares (17,175 units at $291.12), increasing direct ownership by 9% to 203,796 units (SEC Form 4)

      4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

      5/16/25 6:11:47 PM ET
      $UNH
      Medical Specialities
      Health Care
    • CEO, UHG Hemsley Stephen J bought $25,019,019 worth of shares (86,700 units at $288.57), increasing direct ownership by 15% to 679,493 units (SEC Form 4)

      4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

      5/16/25 6:11:45 PM ET
      $UNH
      Medical Specialities
      Health Care
    • Director Flynn Timothy Patrick bought $491,786 worth of shares (1,533 units at $320.80) (SEC Form 4)

      4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

      5/16/25 12:28:22 PM ET
      $UNH
      Medical Specialities
      Health Care
    • UnitedHealth Group Investors: Please contact the Portnoy Law Firm to recover your losses. July 7, 2025 Deadline to file Lead Plaintiff Motion.

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) --  The Portnoy Law Firm advises UnitedHealth Group ("UnitedHealth" or the "Company") (NYSE:UNH) UnitedHealth investors have until July 7, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. UnitedHealth is a health insurance and health care services pr

      5/13/25 5:59:56 PM ET
      $UNH
      Medical Specialities
      Health Care
    • UnitedHealth Group Announces Leadership Transition

      Stephen J. Hemsley named Chief Executive Officer Company suspends 2025 outlook as medical expenditures expected to be higher than anticipated Company expects to return to growth in 2026 UnitedHealth Group (NYSE:UNH) today announced the appointment of Stephen J. Hemsley as its chief executive officer, effective immediately, following Andrew Witty's decision to step down as CEO for personal reasons. Hemsley, who served as company CEO from 2006-2017, will remain chairman of the company's Board of Directors and Witty will serve as a senior adviser to Hemsley. "We are grateful for Andrew's stewardship of UnitedHealth Group, especially during some of the most challenging times any company

      5/13/25 6:30:00 AM ET
      $UNH
      Medical Specialities
      Health Care
    • CareXM adds Home-Based Care Industry Leader, Carla Davis, to its Board of Directors

      CareXM, the leading provider of clinical triage and virtual care coordination solutions for post-acute care, announced today that Carla Davis has been appointed as an independent member of its Board of Directors, effective May 6, 2025. Davis joins the Board following an impressive 30-year career in home health and hospice, serving most recently as Senior Vice President of Hospice Operations at LHC Group. "We are excited to welcome Carla to CareXM's Board of Directors," said Si Luo, chief executive officer at CareXM. "Carla was one of the first customer leaders I had the privilege of meeting after joining CareXM, and from our first conversation, her unwavering commitment to advancing the pa

      5/7/25 8:46:00 AM ET
      $UNH
      Medical Specialities
      Health Care
    • CEO, UHG Hemsley Stephen J gifted 2,525 shares, decreasing direct ownership by 0.67% to 374,353 units (SEC Form 4)

      4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

      5/22/25 4:13:29 PM ET
      $UNH
      Medical Specialities
      Health Care
    • President & CFO Rex John F bought $4,999,919 worth of shares (17,175 units at $291.12), increasing direct ownership by 9% to 203,796 units (SEC Form 4)

      4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

      5/16/25 6:11:47 PM ET
      $UNH
      Medical Specialities
      Health Care
    • CEO, UHG Hemsley Stephen J bought $25,019,019 worth of shares (86,700 units at $288.57), increasing direct ownership by 15% to 679,493 units (SEC Form 4)

      4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

      5/16/25 6:11:45 PM ET
      $UNH
      Medical Specialities
      Health Care